Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study

Min Jin Ha, Akshara Singareeka Raghavendra, Nicole M. Kettner, Wei Qiao, Senthil Damodaran, Rachel M. Layman, Kelly K. Hunt, Yu Shen, Debu Tripathy, Khandan Keyomarsi

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study'. Together they form a unique fingerprint.

Medicine & Life Sciences